NAV

Zeaxanthin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Zeaxanthin
DrugBank Accession Number
DB11176
Background

Zeaxanthin is a most common carotenoid alcohols found in nature that is involved in the xanthophyll cycle. As a coexistent isomer of lutein, zeaxanthin is synthesized in plants and some micro-organisms. It gives the distinct yellow color to many vegetables and other plants including paprika, corn, saffron and wolfberries. Zeaxanthin is one of the two primary xanthophyll carotenoids contained within the retina of the eye and plays a predominant component in the central macula. It is available as a dietary supplement for eye health benefits and potential prevention of age-related macular degeneration. Zeaxanthin is also added as a food dye.

Type
Small Molecule
Groups
Approved, Investigational
Structure
3D
Similar Structures
Weight
Average: 568.886
Monoisotopic: 568.428031043
Chemical Formula
C40H56O2
Synonyms
Not Available
External IDs
  • E 161H
  • E-161H(I)
  • INS NO.161H(I)
  • INS-161H(I)
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Therapies
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
  • Take with or without food.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Vista Advanced AREDS2 FormulaZeaxanthin (1 mg/966.47mg) + Ascorbic acid (250 mg/966.47mg) + Copper gluconate (1 mg/966.47mg) + Glutathione (25 mg/966.47mg) + Lutein (5 mg/966.47mg) + Selenium (0.0275 mg/966.47mg) + Vitamin E (137.5 mg/966.47mg)CapsuleOralRed Wedding LLC2020-09-01Not applicableUS flag
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
MacuvexZeaxanthin (1 mg/1) + Ascorbic acid (250 mg/1) + Copper (1 mg/1) + Folic acid (1 mg/1) + Lutein (5 mg/1) + Zinc oxide (40 mg/1) + alpha-Tocopherol acetate (200 [iU]/1)CapsuleOralSterling-knight Pharmaceuticals,LLC2014-11-162015-07-28US flag
MacuzinZeaxanthin (2 mg/1) + Ascorbic acid (500 mg/1) + Copper (2 mg/1) + DL-alpha tocopheryl acetate (400 [iU]/1) + Folic acid (1 mg/1) + Lutein (10 mg/1) + Zinc oxide (80 mg/1)CapsuleOralSterling-Knight Pharmaceuticals, LLC2015-04-302018-07-30US flag
OcuvelZeaxanthin (2 mg/1) + Ascorbic acid (500 mg/1) + Copper (2 mg/1) + Folic acid (1 mg/1) + Lutein (10 mg/1) + Zinc oxide (80 mg/1) + alpha-Tocopherol acetate (400 [iU]/1)CapsuleOralAdler-Stern Pharmaceuticals, LLC2014-11-05Not applicableUS flag
OcuvelZeaxanthin (1 mg/1) + Ascorbic acid (250 mg/1) + Copper (1 mg/1) + Folic acid (0.5 mg/1) + Lutein (5 mg/1) + Zinc oxide (40 mg/1) + alpha-Tocopherol acetate (200 [iU]/1)CapsuleOralAdler-Stern Pharmaceuticals, LLC2014-12-01Not applicableUS flag
TozalZeaxanthin (3 mg/31) + Ascorbic acid (452 mg/31) + Cholecalciferol (1000 [iU]/31) + Copper (1.6 mg/31) + Cyanocobalamin (100 ug/31) + Folic acid (1 mg/31) + Lutein (15 mg/31) + Omega-3 fatty acids (600 mg/31) + Pyridoxine hydrochloride (20 mg/31) + Taurine (400 mg/31) + Vitamin A palmitate (10000 [iU]/31) + Vitamin E (200 [iU]/31) + Zinc picolinate (40 mg/31)Capsule, gelatin coatedOralFocus Laboratories, Inc.2013-06-012015-07-15US flag

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as xanthophylls. These are carotenoids containing an oxygenated carotene backbone. Carotenes are characterized by the presence of two end-groups (mostly cyclohexene rings, but also cyclopentene rings or acyclic groups) linked by a long branched alkyl chain. Carotenes belonging form a subgroup of the carotenoids family. Xanthophylls arise by oxygenation of the carotene backbone.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Prenol lipids
Sub Class
Tetraterpenoids
Direct Parent
Xanthophylls
Alternative Parents
Secondary alcohols / Hydrocarbon derivatives
Substituents
Alcohol / Aliphatic homomonocyclic compound / Hydrocarbon derivative / Organic oxygen compound / Organooxygen compound / Secondary alcohol / Xanthophyll
Molecular Framework
Aliphatic homomonocyclic compounds
External Descriptors
carotenol (CHEBI:27547) / C40 isoprenoids (tetraterpenes), Carotenoids (C06098) / C40 isoprenoids (tetraterpenes) (LMPR01070261)
Affected organisms
Not Available

Chemical Identifiers

UNII
CV0IB81ORO
CAS number
144-68-3
InChI Key
JKQXZKUSFCKOGQ-QAYBQHTQSA-N
InChI
InChI=1S/C40H56O2/c1-29(17-13-19-31(3)21-23-37-33(5)25-35(41)27-39(37,7)8)15-11-12-16-30(2)18-14-20-32(4)22-24-38-34(6)26-36(42)28-40(38,9)10/h11-24,35-36,41-42H,25-28H2,1-10H3/b12-11+,17-13+,18-14+,23-21+,24-22+,29-15+,30-16+,31-19+,32-20+/t35-,36-/m1/s1
IUPAC Name
(1R)-4-[(1E,3E,5E,7E,9E,11E,13E,15E,17E)-18-[(4R)-4-hydroxy-2,6,6-trimethylcyclohex-1-en-1-yl]-3,7,12,16-tetramethyloctadeca-1,3,5,7,9,11,13,15,17-nonaen-1-yl]-3,5,5-trimethylcyclohex-3-en-1-ol
SMILES
C\C(\C=C\C=C(/C)\C=C\C1=C(C)C[C@@H](O)CC1(C)C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C)C[C@@H](O)CC1(C)C

References

General References
Not Available
Human Metabolome Database
HMDB0002789
KEGG Compound
C06098
PubChem Compound
5280899
PubChem Substance
347827933
ChemSpider
4444421
RxNav
39918
ChEBI
27547
ChEMBL
CHEMBL2359248
ZINC
ZINC000008220175
PDBe Ligand
5X6
Wikipedia
Zeaxanthin
PDB Entries
8wey

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentAge - Related Macular Degeneration (AMD) / Cataracts1
2CompletedPreventionNutrient Deficiency / Pregnancy Related1
2CompletedTreatmentNPDR - Non Proliferative Diabetic Retinopathy / Type 2 Diabetes Mellitus1
1RecruitingTreatmentMetastatic Cancer / Metastatic Solid Neoplasm1
1, 2TerminatedOtherGlaucoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
CapsuleOral
Capsule, gelatin coatedOral
TabletOral
Capsule, liquid filledOral
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000649 mg/mLALOGPS
logP8.3ALOGPS
logP8.35Chemaxon
logS-5.9ALOGPS
pKa (Strongest Acidic)18.91Chemaxon
pKa (Strongest Basic)-0.79Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count2Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area40.46 Å2Chemaxon
Rotatable Bond Count10Chemaxon
Refractivity194.95 m3·mol-1Chemaxon
Polarizability73.47 Å3Chemaxon
Number of Rings2Chemaxon
Bioavailability0Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-0udi-2000190000-2cc8481518a353268253
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-014i-0132980000-32b6e1b8a8e7568ad024
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-016s-0106090000-05c0a22672bf46067112
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0j6s-0139260000-7452299e14bd8a4fc78c
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-02bk-0133950000-83807e741889b1873d81
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0f9j-0389260000-92793d0366d8038fa764
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0ina-0033900000-ea0f3e5fb3dac635c057
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-324.8593396
predicted
DarkChem Lite v0.1.0
[M-H]-324.1645396
predicted
DarkChem Lite v0.1.0
[M-H]-324.0957396
predicted
DarkChem Lite v0.1.0
[M-H]-261.269
predicted
DeepCCS 1.0 (2019)
[M+H]+326.5805396
predicted
DarkChem Lite v0.1.0
[M+H]+329.7005396
predicted
DarkChem Lite v0.1.0
[M+H]+329.5139396
predicted
DarkChem Lite v0.1.0
[M+H]+263.16443
predicted
DeepCCS 1.0 (2019)
[M+Na]+324.7397396
predicted
DarkChem Lite v0.1.0
[M+Na]+326.3775396
predicted
DarkChem Lite v0.1.0
[M+Na]+324.7563396
predicted
DarkChem Lite v0.1.0
[M+Na]+269.07205
predicted
DeepCCS 1.0 (2019)

Drug created at December 03, 2015 16:51 / Updated at June 12, 2020 16:53